

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ASCENTAGE PHARMA GROUP INTERNATIONAL

亞盛醫藥集團

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6855)

CHANGE OF COMPANY EMAIL ADDRESS

The board of directors (the “**Board**”) of Ascentage Pharma Group International (the “**Company**”) hereby announces that with effect from November 1, 2022, the contact email address in relation to the investor inquiries of the Company will be changed from “ir@ascentagepharma.com” to “ir@ascentage.com” and the suffixes of all email addresses of the contact persons of the Company will also be changed from “@ascentagepharma.com” to “@ascentage.com”.

By order of the Board
Ascentage Pharma Group International
Dr. Yang Dajun
Chairman and Executive Director

Suzhou, People’s Republic of China, November 1, 2022

As at the date of this announcement, the Board comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng and Dr. Lu Simon Dazhong as non-executive Directors, and Mr. Ye Changqing, Dr. Yin Zheng, Mr. Ren Wei and Dr. David Sidransky as independent non-executive Directors.